Program
bepirovirsen
Also written as “Bepirovirsen”, “GSK3228836” and “IONIS-HBVRx”.
Its studies are mostly in Hepatitis B · Hepatitis B, Chronic, led by GlaxoSmithKline.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 155 open or running | phase 4since Oct 26, 2026 | Dec 1, 2016 | Mar 30, 2027phase 1 · NCT07905157 |
Also a collaborator on its studies: ppd-development-lp and Ionis Pharmaceuticals.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 1, 2016First study: phase 2 study in Hepatitis BFirst studyNCT02981602 · 31 enrolled · Hong Kong, Korea, Republic of
- Jun 23, 2020Phase 2 study in Hepatitis BNCT04449029 · 457 enrolled · United States, Argentina, Bulgaria and more
- Sep 4, 2020Phase 2 study in Hepatitis BNCT04544956 · 12 enrolled · United States, Canada, Netherlands and more
- Dec 15, 2020Phase 2 study in Hepatitis BNCT04676724 · 108 enrolled · United States, Canada, China and more
- Jun 22, 2021Phase 1 study in Hepatitis BNCT04971928 · 24 enrolled · United States
- Jun 29, 2021Phase 2 study in Hepatitis BNCT04954859 · 366 enrolled · United States, Argentina, Australia and more
- Apr 8, 2022Phase 2 study in Hepatitis BNCT05330455 · 74 enrolled · Canada, France, Italy and more
- Nov 21, 20222 phase 3 studies in Hepatitis B, ChronicNCT05630820, NCT05630807
- Sep 22, 2023Phase 1 study in Hepatitis BNCT06058390 · 160 enrolled · United States
- May 15, 2024Phase 1 study in Hepatitis BNCT06422767 · 46 enrolled · United States
- Jul 5, 2024Phase 2 study in Hepatitis BNCT06497504 · 153 enrolled · United States, Argentina, Brazil and more
- Sep 10, 2025Phase 1 study in Hepatitis BNCT07168356 · 32 enrolled · United States
- Oct 23, 2026Phase 1 study in Hepatitis BNCT07905157 · 98 planned
- Oct 26, 2026Phase 4 study in Hepatitis BNCT07908459 · 303 planned
Ahead
- Mar 30, 2027Primary completion: phase 1 study in Hepatitis BNCT07905157
- Apr 22, 2027Primary completion: phase 2 study in Hepatitis BNCT06497504
- Jan 24, 2029Primary completion: phase 2 study in Hepatitis BNCT04954859
- Dec 3, 2030Primary completion: phase 4 study in Hepatitis BNCT07908459
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“mRNA antisense inhibitor”ChEMBL 37, by rule
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07908459Hepatitis B | 4 | Not yet recruiting | Dec 3, 2030 | 303 |
| NCT07905157Hepatitis B | 1 | Not yet recruiting | Mar 30, 2027 | 98 |
| NCT07168356Hepatitis B · United States | 1 | Active, not recruiting | Mar 3, 2026 | 32 |
| NCT06497504Hepatitis B · United States, Argentina, Brazil and more | 2 | Active, not recruiting | Apr 22, 2027 | 153 |
| NCT06422767Hepatitis B · United States | 1 | Completed | Apr 28, 2025 | 46 |
| NCT06058390Hepatitis B · United States | 1 | Completed | May 3, 2024 | 160 |
| NCT05630820Hepatitis B, Chronic · United States, Argentina, Australia and more | 3 | Completed | Nov 3, 2025 | 857 |
| NCT05630807Hepatitis B, Chronic · United States, Argentina, Brazil and more | 3 | Completed | Nov 11, 2025 | 981 |
| NCT05330455Hepatitis B · Canada, France, Italy and more | 2 | Terminated | May 19, 2025 | 74 |
| NCT04954859Hepatitis B · United States, Argentina, Australia and more | 2 | Active, not recruiting | Jan 24, 2029 | 366 |
| NCT04971928Hepatitis B · United States | 1 | Completed | May 12, 2022 | 24 |
| NCT04676724Hepatitis B · United States, Canada, China and more | 2 | Completed | Feb 17, 2023 | 108 |
| NCT04544956Hepatitis B · United States, Canada, Netherlands and more | 2 | Completed | Nov 30, 2023 | 12 |
| NCT04449029Hepatitis B · United States, Argentina, Bulgaria and more | 2 | Completed | Mar 18, 2022 | 457 |
| NCT02981602Hepatitis B · Hong Kong, Korea, Republic of | 2 | Completed | Dec 18, 2019 | 31 |
How it is read
Names in the registry
- “Bepirovirsen”, 10 entries
- “GSK3228836”, 4 entries
- “IONIS-HBVRx”, 1 entry
Conditions, from the studies’ own filings
- Hepatitis B, 9 studies
- Hepatitis B, Chronic, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.